AIM ImmunoTech releases CEO update on Ampligen pancreatic cancer program

The company said the segment covers DURIPANC Phase 2 enrollment and dosing completion, interim observations, Phase 3 planning, and collaborations with AstraZeneca and Erasmus Medical Center.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.